308 related articles for article (PubMed ID: 28061764)
1. Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma.
Jebali M; Elaidi R; Brizard M; Fouque J; Takouchop C; Sabatier B; Oudard S; Medioni J
BMC Cancer; 2017 Jan; 17(1):27. PubMed ID: 28061764
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
[TBL] [Abstract][Full Text] [Related]
3. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
Vogelzang NJ; Hackshaw MD; Hutson TE; Bhowmik D; Yap M; Rembert D; Jonasch E
Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
[TBL] [Abstract][Full Text] [Related]
4. Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.
Weikert S; Kempkensteffen C; Busch J; Johannsen M; Grünwald V; Zimmermann K; Flörcken A; Westermann J; Weinkauf L; Miller K; Keilholz U
World J Urol; 2013 Aug; 31(4):805-9. PubMed ID: 21512806
[TBL] [Abstract][Full Text] [Related]
5. Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.
Blesius A; Beuselinck B; Chevreau C; Ravaud A; Rolland F; Oudard S; Escudier B
Clin Genitourin Cancer; 2013 Jun; 11(2):128-33. PubMed ID: 23332872
[TBL] [Abstract][Full Text] [Related]
6. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.
Harshman LC; Kroeger N; Rha SY; Donskov F; Wood L; Tantravahi SK; Vaishampayan U; Rini BI; Knox J; North S; Ernst S; Yuasa T; Srinivas S; Pal S; Heng DY; Choueiri TK
Clin Genitourin Cancer; 2014 Oct; 12(5):335-40. PubMed ID: 24787966
[TBL] [Abstract][Full Text] [Related]
7. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
[TBL] [Abstract][Full Text] [Related]
8. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.
Voss MH; Bastos DA; Karlo CA; Ajeti A; Hakimi AA; Feldman DR; Hsieh JJ; Molina AM; Patil S; Motzer RJ
Ann Oncol; 2014 Mar; 25(3):663-668. PubMed ID: 24458473
[TBL] [Abstract][Full Text] [Related]
9. Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies.
Patel SB; Stenehjem DD; Gill DM; Tantravahi SK; Agarwal AM; Hsu J; Vuong W; Pal SK; Agarwal N
Clin Genitourin Cancer; 2016 Apr; 14(2):153-9. PubMed ID: 26781820
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08.
Kim KH; Kim JH; Lee JY; Kim HS; Heo SJ; Kim JH; Kim HY; Rha SY
Cancer Res Treat; 2016 Oct; 48(4):1286-1292. PubMed ID: 26875195
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial.
Porta C; Calvo E; Climent MA; Vaishampayan U; Osanto S; Ravaud A; Bracarda S; Hutson TE; Escudier B; Grünwald V; Kim D; Panneerselvam A; Anak O; Motzer RJ
Eur Urol; 2012 Apr; 61(4):826-33. PubMed ID: 22297244
[TBL] [Abstract][Full Text] [Related]
12. Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma.
Nozawa M; Ohzeki T; Tamada S; Hongo F; Anai S; Fujimoto K; Miki T; Nakatani T; Fukasawa S; Uemura H
Int J Clin Oncol; 2015 Aug; 20(4):790-5. PubMed ID: 25342378
[TBL] [Abstract][Full Text] [Related]
13. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
[TBL] [Abstract][Full Text] [Related]
14. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor.
Park I; Lee JL; Ahn JH; Lee DH; Lee KH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H
Cancer Chemother Pharmacol; 2015 May; 75(5):1025-35. PubMed ID: 25776906
[TBL] [Abstract][Full Text] [Related]
16. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
[TBL] [Abstract][Full Text] [Related]
17. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network.
Vogelzang NJ; Bhor M; Liu Z; Dhanda R; Hutson TE
Clin Genitourin Cancer; 2013 Jun; 11(2):115-20. PubMed ID: 23063578
[TBL] [Abstract][Full Text] [Related]
18. [Experience with everolimus therapy for patients with metastatic renal cancer in Hungary].
Maráz A; Bodoky G; Dank M; Géczi L; Kahán Z; Mangel L; Révész J; Szűcs M
Magy Onkol; 2014 Mar; 58(1):4-9. PubMed ID: 24712001
[TBL] [Abstract][Full Text] [Related]
19. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
Busch J; Seidel C; Erber B; Issever AS; Hinz S; Kempkensteffen C; Magheli A; Miller K; Grünwald V; Weikert S
Eur Urol; 2013 Jul; 64(1):62-70. PubMed ID: 22999519
[TBL] [Abstract][Full Text] [Related]
20. mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response.
Lamuraglia M; Raslan S; Elaidi R; Oudard S; Escudier B; Slimane K; Penna RR; Wagner M; Lucidarme O
Eur Radiol; 2016 Jan; 26(1):278-85. PubMed ID: 25953002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]